Equities

Microbot Medical Inc

Microbot Medical Inc

Actions
  • Price (EUR)1.04
  • Today's Change0.03 / 2.97%
  • Shares traded0.00
  • 1 Year change-51.04%
  • Beta--
Data delayed at least 15 minutes, as of Mar 28 2024 08:05 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Microbot Medical Inc. is a pre-clinical medical device company. The Company specializes in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Its technological platforms include LIBERTY, NovaCross, One & Done, ViRob and TipCAT. LIBERTY is designed to maneuver guidewires and over-the-wire devices, such as microcatheters within the body’s vasculature. It eliminates the need for capital equipment requiring dedicated Cath-lab rooms, as well as dedicated staff. The ViRob is an autonomous crawling micro-robot that can be controlled remotely or within the body. The TipCAT is a disposable, self-propelled locomotive device that is specially designed to advance in tubular anatomies. The TipCAT is a mechanism comprising a series of interconnected balloons at the device’s tip that provides the TipCAT with its forward locomotion capability. It is also focused on the development of a multi generation pipeline portfolio.

  • Revenue in USD (TTM)0.00
  • Net income in USD-10.74m
  • Incorporated1988
  • Employees22.00
  • Location
    Microbot Medical Inc25 RECREATION PARK DR SUITE 108HINGHAM 02043United StatesUSA
  • Phone+1 (908) 938-5561
  • Fax+1 (302) 655-5049
  • Websitehttp://www.microbotmedical.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.